890302-02-0 Usage
Uses
Used in Pharmaceutical Industry:
2-Amino-6-(trifluoromethyl)nicotinic acid is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-6-(trifluoromethyl)nicotinic acid serves as a key intermediate in the production of agrochemicals. Its incorporation into these compounds can enhance their performance, such as increasing their stability, bioavailability, or target specificity.
Used as an Intermediate in Organic Synthesis:
2-Amino-6-(trifluoromethyl)nicotinic acid is utilized as an intermediate in the synthesis of other organic compounds. Its reactivity and functional groups make it a suitable candidate for further chemical modifications, leading to the creation of novel molecules with diverse applications.
Used in Biological Research:
2-Amino-6-(trifluoromethyl)nicotinic acid is studied for its potential biological activities, such as its ability to inhibit specific enzymes. This property can be harnessed in the development of drugs targeting enzyme-related diseases, offering new therapeutic options for patients.
Used in Disease Treatment:
2-aMino-6-(trifluoroMethyl)nicotinic acid has shown promise in the treatment of various diseases due to its potential biological activities. Its ability to modulate enzyme functions and interact with biological targets makes it a candidate for further research and development in the medical field, potentially leading to new treatments and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 890302-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,0,3,0 and 2 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 890302-02:
(8*8)+(7*9)+(6*0)+(5*3)+(4*0)+(3*2)+(2*0)+(1*2)=150
150 % 10 = 0
So 890302-02-0 is a valid CAS Registry Number.
890302-02-0Relevant academic research and scientific papers
Substituted fused pyrimidinone and dihydro-pyrimidone
-
Paragraph 0182-0184, (2016/10/08)
The use of substituted fused pyrimidinones and dihydropyrimidinones of the formula (I) or salts thereof where the radicals of the formula (I) are each as defined in the description, for enhancing stress tolerance in plants to abiotic stress, and for invigorating plant growth and/or for increasing plant yield.
HETEROCYCLIC JAK KINASE INHIBITORS
-
Page/Page column 77, (2010/04/27)
The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer
Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors
Thomas, Allen A.,Le Huerou,De Meese,Gunawardana, Indrani,Kaplan, Tomas,Romoff, Todd T.,Gonzales, Stephen S.,Condroski, Kevin,Boyd, Steven A.,Ballard, Josh,Bernat, Bryan,DeWolf, Walter,Han, May,Lee, Patrice,Lemieux, Christine,Pedersen, Robin,Pheneger, Jed,Poch, Greg,Smith, Darin,Sullivan, Francis,Weiler, Solly,Wright, S. Kirk,Lin, Jie,Brandhuber, Barb,Vigers, Guy
, p. 2206 - 2210 (2008/12/20)
Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mice with xenografted HCT-116 tumors were dosed with 1 ('N3′-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of thiamine, the co-factor of transketolase. Transketolase activity was almost completely suppressed in blood, spleen, and tumor cells, but there was little effect on the activity of the other thiamine-utilizing enzymes α-ketoglutarate dehydrogenase or glucose-6-phosphate dehydrogenase. Synthesis and SAR of transketolase inhibitors is described.
